Abstract:Background Microtubule-associated proteins (MAPs) have been considered to play significant roles in the tumor evolution of non-small cell lung cancer (NSCLC). Nevertheless, mRNA transcription levels and prognostic value of distinct MAPs in patients with NSCLC remain to be clarified. Methods In this study, the Oncomine database, Gene Expression Profiling Interactive Analysis (GEPIA) database, and Human Protein Atlas were utilized to analyze the relationship between mRNA/protein expression of different MAPs and clinical characteristics in NSCLC patients, including tumor type and pathological stage. The correlation between the transcription level of MAPs and overall survival (OS) of NSCLC patients was analyzed by Kaplan-Meier plotter. Besides, 50 frequently altered neighbor genes of the MAPs were screened out, and a network has been constructed via the cBioPortal and Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) dataset. Meanwhile, we performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis on the expression data of MAPs and their 50 frequently altered neighbor genes in NSCLC tissues. Furthermore, The Cancer Immunome Atlas (TCIA) was utilized to analyze the relationship between MAP expression and the response to immunotherapy. Finally, we used reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to verify the expression of MAPs in 20 patients with NSCLC. Results The present study discovered that the mRNA transcription levels of MAP7/7D2 were enriched in NSCLC tissues, while those of the MAP2/4/6/7D3 were lower in NSCLC specimens than those in control specimens. The mRNA transcription level of MAP6 was significantly associated with the advanced stage of NSCLC. Besides, survival analysis indicated that higher mRNA expressions of MAP2/4/6/7/7D3 were correlated considerably with favorable OS of NSCLC patients, whereas increased mRNA expression levels of MAP1A/1S were associated with poor OS. Moreover, the expression of MAP1A/1B/1S/4/6/7D1/7D3 was significantly correlated with immunophenoscore (IPS) in NSCLC patients. Conclusions Our analysis indicated that MAP1A/1S could serve as potential personalized therapeutic targets for patients with NSCLC, and the enriched MAP2/4/6/7/7D3 expression could serve as a biomarker for favorable prognosis in NSCLC. Besides, the expression of MAP1A/1B/1S/4/6/7D1/7D3 was closely related to the response to immunotherapy. Taken together, MAP expression has potential application value in the clinical treatment and prognosis assessment of NSCLC patients, and further verifiable experiments can be conducted to verify our results.

Expression of Mucin Family Proteins in Non-Small-Cell Lung Cancer and Its Role in Evaluation of Prognosis

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

Integrated Bioinformatics Analysis and Clinical Validation Reveals That High Expression of Mucin 1 in Intrahepatic Cholangiocarcinoma Predicts Recurrence after Curative Resection.

Clinicopathological and Prognostic Significance of MUC4 Expression in Cancers: Evidence from Meta-Analysis.

Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma from Chinese Patients.

Expression and Prognostic Relevance of MUC1 in Stage IB Non-Small Cell Lung Cancer

Value of Peripheral Blood MUC1 Mrna and Cyfra21-ⅰ in Diagnosis of Non-Small Cell Lung Carcinoma

Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma.

MUC1 Overexpression Predicts Worse Survival in Patients with Non-Small Cell Lung Cancer: Evidence from an Updated Meta-Analysis.

Comprehensive Analysis of the Mechanism and Treatment Significance of Mucins in Lung Cancer

Clinical Significance of MUC1 Mrna Expression in Peripheral Blood and Bone Marrow in Patients with Lung Cancer

Expression of Microtubule-Associated Proteins in Relation to Prognosis and Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.

MUC3A Promotes Non-Small Cell Lung Cancer Progress Via Activating NFκB Pathway and Attenuates Radiosensitivity

Expression of Profile of MUC1 mRNA in Lymph Node from Patients with Non-small Cell Lung Carcinoma Detected and Its Clinical Significance

Prognostic Value of MUC1 and its Correlation with Tumor-Infiltrating Immune Cells in Breast Cancer

Prognostic significance of minichromosome maintenance mRNA expression in human lung adenocarcinoma

Minichromosome Maintenance Gene Family: Potential Therapeutic Targets and Prognostic Biomarkers for Lung Squamous Cell Carcinoma.

Preferential Localization of MUC1 Glycoprotein in Exosomes Secreted by Non-Small Cell Lung Carcinoma Cells.

Association of Mucin Family Members with Prognostic Significance in Pancreatic Cancer Patients: A Meta-Analysis

A pan-cancer analysis of MUC family genes as potential biomarkers for immune checkpoint therapy.

The Expression and Prognostic Significance of Mucin 13 and Mucin 20 in Esophageal Squamous Cell Carcinoma